Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib plus bevacizumab for MET exon 14 skipping non-squamous NSCLC (Phase II, single-arm)
ChiCTR2500104259Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebreltinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: objective response rate (ORR) by investigator and progression-free survival (PFS) by investigator. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
vebreltinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500104259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104259.